Please wait...
About This Project
OncoSynergy, Inc.
The Ebola outbreak in west Africa has been declared a global emergency by the WHO with over 1,000 victims and no approved therapies. OncoSynergy is developing a readily manufactured experimental cancer drug, OS2966, which coincidentally targets the receptor hijacked by ebola to infect cells. This project aims to demonstrate that OS2966 inhibits ebola infection of human cells thus providing the impetus for expediting OS2966 for treatment of ebola.
Recent Lab Notes From This Project
Browse Other Projects on Experiment
Related Projects
How does hemlock tree decline impact bird bioindicators and ecosystem condition?
An invasive insect, the Hemlock Woolly Adelgid (HWA), is causing Eastern Hemlock tree decline in the Appalachian...
Do turtles have enough variation in adaptive genes to keep pace with climate change?
Climate change is expected to have impacts on biodiversity worldwide. Many species will be faced with a choice...
